Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION

This article was originally published in The Tan Sheet

Executive Summary

REYE SYNDROME REVISED WARNING OPPOSED BY P&G, ASPIRIN FOUNDATION of America in comments on FDA's Oct. 20 proposal to revise the Reye syndrome warning on aspirin and to require the warning on both aspirin and non-aspirin salicylate products. The two commenters objected to the proposal, in part, on the grounds that the revised warning, which is based on the voluntary warning used for Procter & Gamble's bismuth subsalicylate product, Pepto- Bismol, does not take into consideration the different conditions for which aspirin and other salicylate products are used.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082335

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel